Effect of prior treatment with resveratrol on density and structure of rat long bones under tail-suspension.
Physical inactivity during space flight or prolonged bed rest causes rapid and marked loss of bone mass in humans. Resveratrol, a red wine polyphenol that is currently under study for its therapeutic antioxidant properties, has been shown to significantly modulate biomarkers of bone metabolism, i.e., to promote osteoblast differentiation and to prevent bone loss induced by estrogen deficiency. However, there is no direct evidence supporting its inhibitory effect toward bone loss during physical inactivity. In the present study, effects of resveratrol on bone mineral density (BMD), bone mineral content, and bone structure were examined in the femora and tibiae of tail-suspended and unsuspended rats using X-ray micro-computed tomography (micro-CT). Rats were treated with 400 mg/kg/day of resveratrol for 45 days and half of them were suspended during the last 2 weeks of treatment. Suspension caused a decrease in tibial and femoral BMD and deterioration of trabecular and cortical bone. Bone deterioration during suspension was paralleled by increased bone marrow area, which could be caused by an increase in stromal cells with osteoclastogenic potential or in adipocytes. Resveratrol had a preventive effect against bone loss induced by hindlimb immobilization. In particular, trabecular bone in the proximal tibial metaphysis was totally preserved in rats treated with resveratrol before tail-suspension.
Habold
Caroline
C
Institut Pluridisciplinaire Hubert Curien, CNRS UMR 7178, Université de Strasbourg, 23 rue du Loess, Strasbourg Cedex 2, France. caroline.habold@c-strasbourg.fr
Momken
Iman
I
Ouadi
Ali
A
Bekaert
Virgile
V
Brasse
David
D
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D005269:Femur / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D013977:Tibia / Q000187:drug effects / Q000378:metabolism; D055114:X-Ray Microtomography
D013267:Stilbenes; D000077185:Resveratrol
Lancet. 2000 May 6;355(9215):1607-11
10821365
J Cell Sci. 1987 Jun;87 ( Pt 5):731-8
3499442
Bone. 1995 Oct;17(4 Suppl):353S-364S
8579938
J Bone Miner Res. 2004 Jun;19(6):1006-12
15125798
Phys Med Biol. 2009 Apr 7;54(7):2147-61
19287088
Cell Metab. 2008 Aug;8(2):157-68
18599363
Bone. 1998 May;22(5 Suppl):139S-143S
9600771
Am J Physiol. 1999 Jul;277(1 Pt 2):R1-10
10409251
Cell Tissue Kinet. 1987 May;20(3):263-72
3690622
J Med Food. 2005 Spring;8(1):14-9
15857203
Bone. 2002 Jul;31(1):149-57
12110428
Bone. 2000 Aug;27(2):233-9
10913916
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14138-43
9391166
FASEB J. 2003 Nov;17(14):1975-85
14597667
Int J Oncol. 2003 Jul;23(1):17-28
12792772
J Bone Miner Res. 2002 Sep;17(9):1639-45
12211434
J Appl Physiol (1985). 1999 Jun;86(6):1841-6
10368347
Endocrinology. 2007 Jul;148(7):3419-25
17431002
Proc Natl Acad Sci U S A. 1985 Dec;82(23):8213-7
3865222
J Bone Miner Metab. 2002;20(4):216-22
12115067
Phys Med Biol. 2005 Dec 21;50(24):5799-811
16333156
J Comput Assist Tomogr. 1980 Aug;4(4):493-500
7391292
J Pharmacol Exp Ther. 1999 Oct;291(1):321-8
10490920
Aviat Space Environ Med. 1987 Jan;58(1):63-8
3814035
J Clin Invest. 1987 Nov;80(5):1261-9
3500182
Endocrinology. 1999 Jan;140(1):50-4
9886806
Planta Med. 2008 Jun;74(8):794-801
18537073
J Bone Miner Res. 2004 Nov;19(11):1771-8
15476576
J Bone Miner Res. 2002 Apr;17(4):668-77
11918224
J Pediatr Endocrinol Metab. 1998;11(3):421-5
11517958
J Bone Miner Res. 2000 Nov;15(11):2169-77
11092397
J Agric Food Chem. 1999 Aug;47(8):3223-7
10552635
Science. 1978 Sep 22;201(4361):1138-41
150643
Bone. 1998 Jan;22(1):1-6
9437507
Clin Rheumatol. 1989 Jun;8 Suppl 2:95-103
2667875
Cancer Res. 2005 Nov 1;65(21):9943-52
16267019
Am J Physiol. 1993 May;264(5 Pt 1):E790-9
8498500
FASEB J. 1995 Mar;9(5):441-5
7896017
J Bone Miner Res. 1995 Mar;10(3):415-23
7785463
J Bone Miner Res. 2002 Apr;17(4):661-7
11918223